Paul Fioravanti is a veteran interim executive. He is a turnaround expert who has been in some 90 engagements across 40 industries — as a CEO, COO, CTO (Chief Transformation Officer, CRO (Chief Restructuring Officer), General Manager or President.
So he knows a thing or two about how to get things done.
In our most recent Master Class video, InterimExecs CEO Robert Jordan talks with Fioravanti about his turnaround process and, in particular, his experience turning around Avara Pharmaceuticals.
Avara is a private equity-backed Big Pharma rollup that posted a loss of $45,000 and faced an imminent cash crisis and looming insolvency before Fioravanti came in as interim Chief Executive Officer. Thirteen months later, the company was $32 million positive and had achieved financial stability.
Here’s how he did it.